Named on 7 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2024-03-21 to 2026-10-01
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
TriGemX Bio A biotechnology company focused on developing a medicines for the treatment of migraine | Funding round Verified against 4 of 11 sources | $94M | 2026-10-01 | [ LEAD ] |
Vaderis Therapeutics Breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $152M | 2026-08-11 | [ LEAD ] |
Ollin Biosciences Ollin sells innovative therapies targeting serious eye diseases for patients. | Series B Verified against 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $330M | 2026-06-24 | [ LEAD ] |
Korsana Korsana develops advanced therapeutics aimed at treating neurodegenerative diseases, particularly focusing on Alzheimer's disease. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2026-02-18 | [ LEAD ] |
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus. | Series D+ Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2026-01-12 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ PART ] |